- Home
- STRM vs SLGL Comparison
STRM vs SLGL Comparison
Compare STRM & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRM
- SLGL
- Stock Information
- Founded
- STRM 1989
- SLGL 1997
- Country
- STRM United States
- SLGL Israel
- Employees
- STRM N/A
- SLGL N/A
- Industry
- STRM EDP Services
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- STRM Technology
- SLGL Health Care
- Exchange
- STRM Nasdaq
- SLGL Nasdaq
- Market Cap
- STRM 22.3M
- SLGL 19.3M
- IPO Year
- STRM 1996
- SLGL 2018
- Fundamental
- Price
- STRM $5.19
- SLGL $7.33
- Analyst Decision
- STRM
- SLGL Buy
- Analyst Count
- STRM 0
- SLGL 1
- Target Price
- STRM N/A
- SLGL $40.00
- AVG Volume (30 Days)
- STRM 38.1K
- SLGL 25.1K
- Earning Date
- STRM 06-16-2025
- SLGL 08-15-2025
- Dividend Yield
- STRM N/A
- SLGL N/A
- EPS Growth
- STRM N/A
- SLGL N/A
- EPS
- STRM N/A
- SLGL N/A
- Revenue
- STRM $18,381,000.00
- SLGL $12,103,000.00
- Revenue This Year
- STRM $18.64
- SLGL N/A
- Revenue Next Year
- STRM N/A
- SLGL $31.17
- P/E Ratio
- STRM N/A
- SLGL N/A
- Revenue Growth
- STRM N/A
- SLGL 603.66
- 52 Week Low
- STRM $1.82
- SLGL $3.34
- 52 Week High
- STRM $9.45
- SLGL $16.50
- Technical
- Relative Strength Index (RSI)
- STRM 79.51
- SLGL 51.88
- Support Level
- STRM $5.15
- SLGL $7.02
- Resistance Level
- STRM $5.24
- SLGL $7.40
- Average True Range (ATR)
- STRM 0.03
- SLGL 0.34
- MACD
- STRM -0.09
- SLGL 0.01
- Stochastic Oscillator
- STRM 80.00
- SLGL 35.79
About STRM Streamline Health Solutions Inc.
Streamline Health Solutions Inc provides transformational data-driven solutions for healthcare organizations. It provides computer software-based solutions through its looking glass platform. Its solutions include coding and CDI, coding audit, and financial management solutions. It offers various services, such as custom integration services, training services, electronic image conversion and database monitoring services. It sells its solutions and services in North America to hospitals and health systems, including physician practices, through its direct sales force and its reseller partnerships.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.